ICER plans to assess the comparative clinical effectiveness and value of inclisiran (Novartis) and bempedoic acid (NexletolTM, Esperion Therapeutics, Inc.) for treatment of high cholesterol in the setting of heterozygous familial hypercholesterolemia or secondary prevention of ASCVD. Inclisiran is currently undergoing FDA review, with an anticipated decision expected at the end of this year. Bempedoic acid received FDA approval in February 2020.

Interventions of interest:

  • inclisiran (Novartis)
  • bempedoic acid (NexletolTM, Esperion Therapeutics, Inc.)
  • bempedoic acid/ezetimibe (Nexlizet™, Esperion Therapeutics, Inc.)

For questions or additional information, please contact Maggie O’Grady at

View Stakeholder List